4D Molecular Therapeutics, Inc. (FDMT)

US — Healthcare Sector

Peers: TCRR RVMD BDTX BCEL PASG IPSC EWTX CCCC MLYS CGEM BMEA STOK AKRO FIXX GOSS REPL NVCT LYRA KRON

Automate Your Wheel Strategy on FDMT

With Tiblio's Option Bot, you can configure your own wheel strategy including FDMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol FDMT
Rev/Share 0.0002
Book/Share 8.4264
PB 0.4901
Debt/Equity 0.0508
CurrentRatio 12.3635
ROIC -0.4112

MktCap 191320598.0
FreeCF/Share -2.7535
PFCF -1.2464
PE -1.3048
Debt/Assets 0.0463
DivYield 0
ROE -0.3327

Rating B-
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 5
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Downgrade	FDMT	BMO Capital Markets	Outperform	Market Perform	$40	$15	Jan. 13, 2025
Downgrade	FDMT	Cantor Fitzgerald	Overweight	Neutral	--	--	Sept. 23, 2024

News

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

FDMT
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME).

image for news 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

4DMT to Participate in Upcoming Investor Conferences

FDMT
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings.

4DMT to Participate in Upcoming Investor Conferences

FDMT
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

FDMT
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME.

image for news 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

FDMT
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

About 4D Molecular Therapeutics, Inc. (FDMT)

IPO Date 2020-12-11
Website https://www.4dmoleculartherapeutics.com
Industry Biotechnology
CEO Dr. David H. Kirn M.D.
Employees 227

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.